Dnca Finance Cuts Stake in Zoetis Inc. $ZTS

Dnca Finance cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 66.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,800 shares of the company’s stock after selling 40,000 shares during the quarter. Dnca Finance’s holdings in Zoetis were worth $2,897,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in ZTS. Brighton Jones LLC grew its holdings in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares during the last quarter. Empowered Funds LLC lifted its stake in Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after purchasing an additional 657 shares during the last quarter. Intech Investment Management LLC lifted its stake in Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC boosted its position in Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after buying an additional 1,422 shares during the period. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Zoetis during the second quarter valued at about $814,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $115.62 on Friday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The company has a 50-day moving average price of $125.34 and a 200-day moving average price of $131.91. The company has a market cap of $48.81 billion, a price-to-earnings ratio of 19.21, a price-to-earnings-growth ratio of 1.76 and a beta of 0.95. Zoetis Inc. has a 12 month low of $114.47 and a 12 month high of $172.23.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same period last year, the firm earned $1.40 earnings per share. Zoetis’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Analyst Ratings Changes

ZTS has been the topic of several analyst reports. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a report on Tuesday. BTIG Research restated a “buy” rating and set a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Weiss Ratings upgraded Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday. Bank of America lifted their price target on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.